Merck to evaluate Variational AI’s Enki generative AI platform to design novel and selective small molecules
Variational AI, developer of the Enki generative artificial intelligence (AI) platform for pharmaceutical innovation, announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
“With the Enki™ Platform, chemists do not need to develop their own generative AI models, but can now submit their TPPs and get novel, diverse, selective, and synthesizable lead-like structures in days to move quickly into lead optimization.”
“We are pleased to announce Merck as an early-access user of our Enki™ Platform,” said Handol Kim, CEO, Variational AI. “Merck will evaluate Enki’s ability to generate novel small molecules on targets of their choosing. We built and trained Enki™ as a foundation model that generates novel, selective, and synthesizable lead-like structures. It designs novel molecules how other generative AI foundation models like DALL-E and Midjourney create novel images based on text prompts. In our case, a target product profile (TPP) is used as the series of prompts to describe the molecules in the language of chemistry. Enki™ then rapidly generates structures that meet the TPP.”
Recommended AI News: Announcing the New MLPerf Client Working Group
“Adoption of AI for pharmaceutical innovation is accelerating, but it is being led by companies using their proprietary AI to discover and develop their own assets.” Explained Kim, “With the Enki™ Platform, chemists do not need to develop their own generative AI models, but can now submit their TPPs and get novel, diverse, selective, and synthesizable lead-like structures in days to move quickly into lead optimization.”
Recommended AI News: Versa Networks Launches Industry’s First Unified SASE Gateway that Scales Beyond 100 Gbps
The collaboration is supported by CQDM under the Quantum Leap program.
“CQDM is pleased to have facilitated the establishment of collaborations for Variational AI by creating beneficial links with Merck, a global biopharmaceutical organization. These links between early-stage Canadian companies and the biopharmaceutical industry are critical for the growth of the Canadian life sciences sector,” said Jesse Paterson, Senior Director, BD.
Recommended AI News: ON24 Unveils its Next Generation Platform, Unleashing a New Era of AI-powered Intelligent Engagement
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
Comments are closed.